Related Experiment Video
Updated: Jun 14, 2026

Behavioral Assessments of Spontaneous Locomotion in a Murine MPTP-induced Parkinson's Disease Model
Published on: January 7, 2019
A trojan horse for Parkinson's disease
1Center for Neurologic Diseases, Brigham and Women's Hospital, Harvard Medical School, 65 Landsdowne Street, Cambridge, MA 02139, USA. yi_hu@hms.harvard.edu
Pathogenic mutations in leucine-rich repeat kinase 2 (LRRK2) cause Parkinson's disease (PD). LRRK2 kinase activity, while linked to PD, may not be essential for neuron survival, suggesting its inhibition could be therapeutic.
Area of Science:
- Neuroscience
- Genetics
- Pharmacology
Background:
- Pathogenic mutations in leucine-rich repeat kinase 2 (LRRK2) are a significant genetic factor in late-onset Parkinson's disease (PD).
- Initial research suggested a strong link between LRRK2's intrinsic kinase activity and the disease's pathogenesis.
Purpose of the Study:
- To investigate the role of LRRK2 kinase activity in Parkinson's disease pathogenesis.
- To determine if LRRK2 kinase activity is essential for neuron survival and neuroprotection.
Main Methods:
- Analysis of pathogenic LRRK2 mutations.
- Assessment of LRRK2 kinase activity in relation to neuron survival and neurotoxicity.
Main Results:
- LRRK2 kinase activity may be dispensable for maintaining neuron survival.
- The protective functions of LRRK2 against neurotoxicity might not depend on its kinase activity.
Conclusions:
- The intrinsic kinase activity of LRRK2 may act as a detrimental factor in Parkinson's disease.
- Inhibiting LRRK2 kinase activity presents a potential therapeutic strategy for Parkinson's disease.
Related Concept Videos
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease: Overview
Parkinson Disease l: Introduction
Parkinson Disease ll: Pathophysiology
Poliomyelitis
Alterations in Muscle Tone lll